Consistently, Kamal et al., 2021 found significant CTLA4 upregulation in CRC patients compared to healthy volunteers and suggested that it may be used as an independent prognostic biomarker for survival (55). This evidence concerns the gene CTLA4 and colorectal carcinoma.